Both in Pharmaceuticals
Onconetix vs Apimeds Pharmaceuticals US
Over the past year ONCO returned −99.6% and APUS returned −89.3%; their daily moves had a correlation of -0.20.
ONCO −99.6% APUS −89.3%Growth of $1, one year, split-adjusted
| Metric | ONCO | APUS |
|---|---|---|
| Price | $0.6583 | $2.92 |
| Market cap | $3.9M | $4.4M |
| Today | +15.69% | −1.68% |
| 1 month | −0.4% | −59.0% |
| 6 months | −85.4% | −85.0% |
| Year to date | −99.2% | −82.2% |
| 1 year | −99.6% | — |
| Revenue growth (YoY) | −83.9% | — |
| Gross margin | 25.1% | — |
| Net margin | −16748.3% | — |
| P/E (TTM) | — | — |
| Price / sales | 6.0× | — |
| Net cash | $5.8M | -$8.6M |
| Dividend yield | — | — |
| Volatility (60d) | 159.7% | 263.3% |
| Short % of float | 7.4% | 0.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).